Form 8-K Axovant Sciences Ltd. For: Sep 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
UPDATE: Piper Jaffray Downgrades Axovant Sciences (AXON) to Neutral
September 26, 2017 10:53 AM EDT(Updated - September 26, 2017 11:02 AM EDT)
(updated to add analyst comment)
Piper Jaffray downgraded Axovant Sciences (NASDAQ: AXON) from Overweight to Neutral with a price target of $9.00 (from $32.00).
Analyst Charles Duncan says the pipeline needs to be rebuild... More
Oppenheimer Downgrades Axovant Sciences (AXON) to Perform
September 26, 2017 10:48 AM EDTOppenheimer downgraded Axovant Sciences (NASDAQ: AXON) from Outperform to Perform.
For an analyst ratings summary and ratings history on Axovant Sciences click here. For more ratings news on Axovant Sciences click here.
Shares of Axovant Sciences closed at $24.25 yesterday.
... MoreAxovant Sciences (AXON) Sinks 70% as Trading Resumes
September 26, 2017 7:32 AM EDTAxovant Sciences (NASDAQ: AXON) falls 70% to as trading resumes following trial failure.
